Figure 3
Analysis of HBsAg clearance and HBsAg seroconversion between PEG-IFNα+LAM combination therapy and PEG-IFNα monotherapy (high-quality studies).
Figure 3 | BMC Infectious Diseases
Analysis of HBsAg clearance and HBsAg seroconversion between PEG-IFNα+LAM combination therapy and PEG-IFNα monotherapy (high-quality studies).